1. Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol- J clin oncol 18, 3025, 2000 Conclusion: On the basis of the final analysis of this prospectively treated series of patients, retrospectively analyzed on the basis of the International Prognostic Index, we hypothesize that HDT benefits patients at higher risk who achieve complete remission after induction treatment. J Clin Oncol 18:3025-3030. © 2000 by American

2. Kluin Nelemans HC et al Standard chemotherapy with or without high-dose chemotherapy fo aggressicve non Hodglin’s lynmphoma: randomized phase III EORTC study. Journal of the national cancer Institute 93, 22, 2001 Standard cobination therapies remain the best choice for most patietns with aggressive NHL. We recommend that patients with IPI low or low intermediate risk not be sujected to high- dose chemtherapy and ABMT as a first line therapy